Valerie B Galvan-Turner1, Jenny Chang2, Argyrios Ziogas2, Robert E Bristow3. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, Orange, CA, United States. 2. Department of Epidemiology, University of California Irvine, Irvine, CA, United States. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, Orange, CA, United States. Electronic address: rbristow@uci.edu.
Abstract
OBJECTIVE: To develop an observed-to-expected ratio (O/E) for adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines as a risk-adjusted hospital measure of quality care correlated with disease-specific survival. METHODS: Consecutive patients with stages I-IV epithelial ovarian cancer were identified from the California Cancer Registry (1/1/96-12/31/06). Using a fit logistic regression model, O/E for guideline adherence was calculated for each hospital and distributed into quartiles stratified by hospital annual case volume: lowest O/E quartile or annual hospital case volume <5, middle two O/E quartiles and volume ≥5, and highest O/E quartile and volume ≥5. A multivariable logistic regression model was used to characterize the independent effect of hospital O/E on ovarian cancer-specific survival. RESULTS: Overall, 18,491 patients were treated at 405 hospitals; 37.3% received guideline adherent care. Lowest O/E hospitals (n=285) treated 4661 patients (25.2%), mean O/E=0.77±0.55 and median survival 38.9months (95%CI=36.2-42.0months). Intermediate O/E hospitals (n=85) treated 8715 patients (47.1%), mean O/E=0.87±0.17 and median survival of 50.5months (95% CI=48.4-52.8months). Highest O/E hospitals (n=35) treated 5115 patients (27.7%), mean O/E=1.34±0.14 and median survival of 53.8months (95% CI=50.2-58.2months). After controlling for other variables, treatment at highest O/E hospitals was associated with independent and statistically significant improvement in ovarian cancer-specific survival compared to intermediate O/E (HR=1.06, 95% CI=1.01-1.11) and lowest O/E (1.16, 95% CI=1.10-1.23) hospitals. CONCLUSIONS: Calculation of hospital-specific O/E for NCCN treatment guideline adherence, combined with minimum case volume criterion, as a measure of ovarian cancer quality of care is feasible and is an independent predictor of survival. Published by Elsevier Inc.
OBJECTIVE: To develop an observed-to-expected ratio (O/E) for adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines as a risk-adjusted hospital measure of quality care correlated with disease-specific survival. METHODS: Consecutive patients with stages I-IV epithelial ovarian cancer were identified from the California Cancer Registry (1/1/96-12/31/06). Using a fit logistic regression model, O/E for guideline adherence was calculated for each hospital and distributed into quartiles stratified by hospital annual case volume: lowest O/E quartile or annual hospital case volume <5, middle two O/E quartiles and volume ≥5, and highest O/E quartile and volume ≥5. A multivariable logistic regression model was used to characterize the independent effect of hospital O/E on ovarian cancer-specific survival. RESULTS: Overall, 18,491 patients were treated at 405 hospitals; 37.3% received guideline adherent care. Lowest O/E hospitals (n=285) treated 4661 patients (25.2%), mean O/E=0.77±0.55 and median survival 38.9months (95%CI=36.2-42.0months). Intermediate O/E hospitals (n=85) treated 8715 patients (47.1%), mean O/E=0.87±0.17 and median survival of 50.5months (95% CI=48.4-52.8months). Highest O/E hospitals (n=35) treated 5115 patients (27.7%), mean O/E=1.34±0.14 and median survival of 53.8months (95% CI=50.2-58.2months). After controlling for other variables, treatment at highest O/E hospitals was associated with independent and statistically significant improvement in ovarian cancer-specific survival compared to intermediate O/E (HR=1.06, 95% CI=1.01-1.11) and lowest O/E (1.16, 95% CI=1.10-1.23) hospitals. CONCLUSIONS: Calculation of hospital-specific O/E for NCCN treatment guideline adherence, combined with minimum case volume criterion, as a measure of ovarian cancer quality of care is feasible and is an independent predictor of survival. Published by Elsevier Inc.
Authors: Philipp Harter; Zelal M Muallem; Christine Buhrmann; Dietmar Lorenz; Christine Kaub; Rita Hils; Stefan Kommoss; Florian Heitz; Alexander Traut; Andreas du Bois Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Craig C Earle; Deborah Schrag; Bridget A Neville; K Robin Yabroff; Marie Topor; Angela Fahey; Edward L Trimble; Diane C Bodurka; Robert E Bristow; Michael Carney; Joan L Warren Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Robert E Bristow; Marianna L Zahurak; Teresa P Diaz-Montes; Robert L Giuntoli; Deborah K Armstrong Journal: Gynecol Oncol Date: 2009-09-18 Impact factor: 5.482
Authors: Barbara A Goff; Barbara J Matthews; Eric H Larson; C Holly A Andrilla; Michelle Wynn; Denise M Lishner; Laura-Mae Baldwin Journal: Cancer Date: 2007-05-15 Impact factor: 6.860
Authors: Cheryl Mercado; David Zingmond; Beth Y Karlan; Evan Sekaris; Jenny Gross; Melinda Maggard-Gibbons; James S Tomlinson; Clifford Y Ko Journal: Gynecol Oncol Date: 2010-01-27 Impact factor: 5.482
Authors: Kusum S Mathews; Neha N Goel; Carmen Vargas-Torres; Ashley D Olson; Jing Zhou; Charles A Powell; Madhu Mazumdar; Gregory N Stock; Christopher M McDermott Journal: Lung Date: 2020-06-03 Impact factor: 2.584
Authors: Joseph A Dottino; Weiguo He; Charlotte C Sun; Hui Zhao; Shuangshuang Fu; Karen H Lu; Larissa A Meyer Journal: Gynecol Oncol Date: 2019-06-14 Impact factor: 5.482
Authors: A K Sinno; X Li; R E Thompson; E J Tanner; K L Levinson; R L Stone; S M Temkin; A N Fader; D S Chi; K Long Roche Journal: Gynecol Oncol Date: 2017-03-30 Impact factor: 5.482
Authors: Amy Hawarden; Bryn Russell; Mary Ellen Gee; Fatima Kayali; Andrew Clamp; Emma Jayne Crosbie; Richard John Edmondson Journal: BMC Cancer Date: 2021-04-08 Impact factor: 4.430
Authors: Andres Redondo; Ana Oaknin; Maria Jesus Rubio; Maria-Pilar Barretina-Ginesta; Ana de Juan; Luis Manso; Ignacio Romero; Cristina Martin-Lorente; Andres Poveda; Antonio Gonzalez-Martin Journal: J Ovarian Res Date: 2021-05-26 Impact factor: 4.234